[A20-78] Secukinumab (plaque psoriasis in children and adolescents) - Benefit assessment according to §35a Social Code Book V
Last updated 18.02.2021
Project no.:
A20-78
Commission:
Commission awarded on 31.08.2020 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Skin and hair
Indication:
| Children and adolescents from the age of 6 years with moderate to severe plaque psoriasis who are candidates for systemic therapy |
Result of dossier assessment:
| Added benefit not proven due to lack of suitable study data |
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Federal Joint Committee (G-BA)
2021-0218: A G-BA decision was published.